• 1
    Anderson ED, Forrest AP, Levack PA, et al. Response to endocrine manipulation and oestrogen receptor concentration in large operable primary breast cancer. Br J Cancer. 1989; 60: 223226.
  • 2
    Ellis MJ. Preoperative endocrine therapy for older women with breast cancer: renewed interest in an old idea. Cancer Control. 2000; 7: 557562.
  • 3
    Kaufmann M, von Minckwitz G, Smith R, et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol. 2003; 21: 26002608.
  • 4
    Preece PE, Wood RA, Mackie CR, et al. Tamoxifen as initial sole treatment of localised breast cancer in elderly women: a pilot study. Br Med J (Clin Res Ed). 1982; 284: 869870.
  • 5
    Ellis MJ. Neoadjuvant endocrine therapy for breast cancer: medical perspectives. Clin Cancer Res. 2001; 7: 4388s4391s.
  • 6
    Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997; 15: 24832493.
  • 7
    Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998; 16: 26722685.
  • 8
    Gianni L, Baselga J, Eiermann W, et al. First report of the European Cooperative Trial in operable breast cancer (ECTO): effects of primary systemic therapy (PST) on local-regional disease [abstract 132]. Proc Am Soc Clin Oncol. 2002; 21: 34a.
  • 9
    Jakesz R, for the the ABCSG. Comparison of pre vs postoperative chemotherapy in breast cancer patients. Four-year results of Austrian Breast Colorectal Cancer Study Group (ABCSG) Trial 7 [abstract 125]. Proc Am Soc Clin Oncol. 2001; 20: 32a.
  • 10
    Scholl SM, Fourquet A, Asselain B, et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer. 1994; 30A: 645652.
  • 11
    Smith IE, Lipton L. Preoperative/neoadjuvant medical therapy for early breast cancer. Lancet Oncol. 2001; 2: 561570.
  • 12
    van der Hage JA, van de Velde CJ, Julien JP, et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. 2001; 19: 42244237.
  • 13
    Dixon JM, Renshaw L, Bellamy C, et al. The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study. Clin Cancer Res. 2000; 6: 22292235.
  • 14
    Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol. 2001; 12: 15271532.
  • 15
    Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001; 19: 38083816.
  • 16
    Harper-Wynne CL, Sacks NP, Shenton K, et al. Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer. J Clin Oncol. 2002; 20: 10261035.
  • 17
    Mansi JL, Smith IE, Walsh G, et al. Primary medical therapy for operable breast cancer. Eur J Cancer Clin Oncol. 1989; 25: 16231627.
  • 18
    Milla-Santos A, Milla I, Rallo L, et al. Anastrozole (A) as neoadjuvant (NEO) therapy for hormone-dependent locally advanced breast cancer (LABC) in postmenopausal (PM) patients (pts) [abstract 156]. Proc Am Soc Clin Oncol. 2002; 21: 40a.
  • 19
    Semiglazov V, Semiglazov VV, Ivanov VG, et al. Anastrozole (A) vs tamoxifen (T) vs combine (A + T) as neoadjuvant endocrine therapy of postmenopausal breast cancer patients. Breast. 2003; 12: S39S87.
  • 20
    Dowsett M, MacNeill F, Mehta A, et al. Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients. Br J Cancer. 1991; 64: 887894.
  • 21
    Iveson TJ, Smith IE, Ahern J, et al. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer. Cancer Res. 1993; 53: 266270.
  • 22
    Johnston SR, Smith IE, Doody D, et al. Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer. Cancer Res. 1994; 54: 58755881.
  • 23
    Anderson TJ, Dixon JM, Stuart M, et al. Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal women with large operable breast cancer. Br J Cancer. 2002; 87: 334338.
  • 24
    World Health Organization. WHO Classification of tumours: pathology and genetics of tumours of soft tissue and bone. Lyon: International Agency for Research on Cancer (IARC) Press; 2002.
  • 25
    Buzdar A, Robertson JFR, Eiermann W, et al. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole and exemestane. Cancer. 2002; 95: 20062016.
  • 26
    Pierce LJ, Hutchins LF, Green SR, et al. Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer. J Clin Oncol. 2005; 23: 2429.